LENZ Therapeutics, Inc.

LENZ

LENZ Therapeutics, Inc.

LENZ

Insider Sentiment (TTM):

Last Purchase:2026-03-27Last Sale:2025-11-17Shares Purchased (TTM):53,879Shares Sold (TTM):281,041

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:32,069,635Shares Outstanding:31,352,702Institutional Ownership Pct.:102.29%

Earnings Market Reaction:

Filing Date:2026-08-11Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Series A Convertible Preferred Stock	-	-	-	-	-	-	0	0	0	0	0	0
Temporary Equity Par Or Stated Value Per Share	-	-	-	-	-	-	-	-	-	0.001	0.001	-
Temporary Equity Shares Authorized	-	-	-	-	-	-	-	-	-	54	54	-
Assets
Assets Held For Sale Long Lived Fair Value Disclos…	-	-	-	-	-	-	-	-	-	-	-	0
Series A1 Convertible Preferred Stock	-	-	-	-	-	-	0	0	0	0	0	0
Assets Current
Series B Convertible Preferred Stock	-	-	-	-	-	-	0	0	0	0	0	-
Cash And Cash Equivalents At Carrying Value	24	25	25	25	38	23	20	41	84	200	35	183
Restricted Cash Equivalents	-	-	-	-	-	-	-	-	-	-	2	-
Available For Sale Securities Debt Securities Curr…	-	-	-	-	-	-	-	176	112	13	0	51
Class B Convertible Common Stock	-	-	-	-	-	-	0	0	0	0	0	0
Debt Securities Available For Sale Excluding Accru…	196	234	267	177	172	171	189	-	-	-	31	-
Accounts Receivable Net Current	0	0	0	-	-	-	0	-	-	-	-	-
Inventory Net	4	3	3	1	-	-	0	-	-	-	-	-
Prepaid Expense And Other Assets Current	9	6	6	4	4	4	3	3	3	3	1	5
Restricted Cash Current	-	-	0	0	0	0	0	0	0	0	0	-
Restricted Cash Noncurrent	-	-	-	-	-	-	-	-	-	-	0	2
Assets Current	233	268	301	207	214	198	212	221	199	217	67	239
Available For Sale Securities Debt Securities Nonc…	-	-	-	-	-	-	-	-	-	-	0	0
Property Plant And Equipment Net	1	1	1	1	1	1	1	0	0	0	0	13
Operating Lease Right Of Use Asset	1	1	1	1	1	1	1	2	2	1	0	13
Other Assets Noncurrent	2	2	3	2	2	1	1	1	1	-	0	0
Assets	237	273	306	211	217	201	215	224	203	217	70	266
Liabilities And Stockhold…
Deferred Costs	-	-	-	-	-	-	0	0	0	0	3	-
Deposits Assets Noncurrent	-	-	-	-	-	-	-	-	-	0	-	-
Liabilities Current
Employee Related Liabilities Current	-	-	-	-	-	-	-	-	-	-	2	2
Accounts Payable Current	7	11	4	4	3	4	4	3	4	7	6	4
Accrued Liabilities Current	10	15	17	12	8	5	6	5	4	12	13	-
Liabilities Current	17	26	21	16	10	9	10	8	9	19	19	13
Operating Lease Liability Noncurrent	0	0	0	0	1	1	1	1	1	0	0	50
Other Liabilities	-	-	-	-	-	-	-	-	-	-	-	0
Operating Lease Liability Current	-	-	-	-	-	-	-	-	-	-	0	3
Liabilities	17	26	22	17	11	9	11	9	10	19	20	62
Stockholders Equity
Other Liabilities Noncurrent	-	-	-	-	-	-	0	0	0	0	0	-
Preferred Stock Value	0	0	0	-	-	-	0	-	-	-	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	520	516	511	385	381	352	349	347	315	310	3	548
Retained Earnings Accumulated Deficit	-301	-269	-227	-191	-175	-160	-145	-132	-122	-112	-95	-344
Accumulated Other Comprehensive Income Loss Net Of…	-1	-0	0	0	0	0	0	1	-0	-0	0	-0
Temporary Equity
Stockholders Equity	219	246	284	194	206	192	204	215	193	198	-93	-70
Temporary Equity Carrying Amount Attributable To P…	-	-	-	-	-	-	0	0	0	0	143	-
Liabilities And Stockholders Equity	237	273	306	211	217	201	215	224	203	217	70	266
Preferred Stock Par Or Stated Value Per Share	0	0	0	-	-	-	0	-	-	-	0	0
Preferred Stock Shares Authorized	10	10	10	-	-	-	10	-	-	-	10	10
Preferred Stock Shares Issued	0	0	0	-	-	-	0	-	-	-	0	0
Preferred Stock Shares Outstanding	0	0	0	-	-	-	0	-	-	-	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	300	300	300	300	300	300	300	300	300	300	16	300
Common Stock Shares Issued	31	31	31	29	29	28	28	28	26	26	2	58
Shares Outstanding	31	31	31	29	29	28	28	27	26	26	2	58

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-29.83%	-41.04%	-42.34%	-	-	-	-	-	-	-	-	-
2025	15.23%	19.10%	24.78%	30.04%	37.42%	24.38%	42.15%	-21.43%	-4.80%	12.74%	-18.72%	-25.03%
2024	-5.50%	6.86%	48.15%	1.28%	9.70%	18.85%	10.46%	-2.82%	-23.83%	-20.61%	3.21%	25.24%
2023	-	-	-	-12.25%	-6.72%	-9.09%	-2.17%	20.00%	15.22%	53.86%	52.15%	55.29%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	13.55	10.40	14.23	12.69	20.54	23.09	20.36	28.63	23.23	11.47	3.63	19.05
Quick Ratio	12.81	10.03	13.81	12.39	20.16	22.65	20.10	28.17	22.86	11.30	3.55	18.67
Working Capital	216.07M	242.56M	280.23M	190.68M	203.20M	189.29M	201.51M	212.99M	190.77M	197.79M	48.73M	226.25M
Leverage & Debt
Debt to Equity	0.08	0.11	0.08	0.09	0.05	0.05	0.05	0.04	0.05	0.10	-0.21	-0.89
Debt Ratio	0.07	0.10	0.07	0.08	0.05	0.05	0.05	0.04	0.05	0.09	0.28	0.23
Efficiency & Turnover
Asset Turnover TTM	0.09	0.08	0.07	0.08	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding TTM	8.11	6.45	6.86	-	-	-	-	-	-	-	-	-
Receivables Turnover TTM	44.99	56.56	53.19	-	-	-	-	-	-	-	-	-
Per Share Metrics
Diluted EPS TTM	-4.02	-3.48	-2.85	-2.06	-1.87	-1.73	-2.34	-2.24	-2.71	-15.67	-35.71	-36.13
Free Cash Flow Per Share TTM	-3.09	-2.79	-2.43	-1.05	-1.13	-1.89	-2.81	-2.64	-2.89	-15.17	-30.84	-32.06
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-682.14%	-609.98%	-520.79%	-388.00%	-1,239.16%	-	-	-	-	-	-	-
Net Profit Margin TTM	-633.59%	-561.81%	-469.30%	-336.47%	-1,047.96%	-	-	-	-	-	-	-
Growth Metrics
Net Revenue Growth (1Y)	297.74%	-	-	-	-	-	-	-	-	-	-	-
Net Income Growth (1Y)	140.47%	128.31%	65.02%	-3.17%	-24.58%	-35.44%	-28.87%	-14.20%	-9.39%	-15.86%	-30.76%	-38.42%
EPS Growth (1Y)	115.21%	100.45%	21.88%	-7.81%	-31.21%	-88.94%	-93.45%	-93.81%	-93.08%	-65.21%	1,839.38%	1,632.91%
Valuation Metrics
P/E TTM	-1.41	-2.63	-5.61	-22.58	-15.71	-14.82	-12.34	-10.61	-6.37	-1.42	-0.24	-0.23
P/B TTM	0.81	1.16	1.62	6.86	3.99	3.69	3.01	3.00	2.30	0.53	-0.18	-0.23
P/S TTM	8.96	14.79	26.34	75.97	164.60	-	-	-	-	-	-	-
Market Cap	178.21M	286.88M	461.01M	1.33B	823.00M	707.70M	614.38M	645.07M	442.77M	105.34M	17.10M	16.21M
Enterprise Value	154.00M	262.11M	435.83M	1.30B	785.28M	684.54M	594.11M	603.91M	358.62M	-95.13M	-167.16M	-166.78M
Calculated Values
Free Cash Flow TTM	-96.98M	-87.44M	-70.00M	-30.00M	-31.74M	-52.08M	-59.86M	-71.60M	-73.92M	-71.54M	-60.41M	-62.89M
Net Debt	-24.21M	-24.77M	-25.18M	-25.40M	-37.72M	-23.16M	-20.27M	-41.16M	-84.15M	-200.47M	-184.26M	-182.99M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-03-27Purchase

Owner: George, Jeffrey P.

Title: -

Shares: 5,592

Price/Share: $8.92

Value: $49,880.64

Shares Owned: 5,592

Relationship: Director

Ownership: Direct

2026-03-27Purchase

Owner: Chevallard, Daniel R.

Title: Chief Financial Officer

Shares: 7,500

Price/Share: $8.57

Value: $64,275.00

Shares Owned: 12,886

Relationship: Officer

Ownership: Direct

2026-03-27Purchase

Owner: Schimmelpennink, Evert B.

Title: President, CEO and Secretary

Shares: 28,089

Price/Share: $8.95

Value: $251,396.55

Shares Owned: 77,289

Relationship: Director,Officer

Ownership: Direct

2025-11-17Sale

Owner: Olsson, Shawn

Title: Chief Commercial Officer

Shares: 10,000

Price/Share: $26.06

Value: $260,600.00

Shares Owned: 4,733

Relationship: Officer

Ownership: Direct

2025-11-07Purchase

Owner: Chevallard, Daniel R.

Title: Chief Financial Officer

Shares: 2,198

Price/Share: $22.74

Value: $49,982.52

Shares Owned: 5,386

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-03-27	George, Jeffrey P.	Director	-	Direct	Purchase	5,592	8.92	$49,880.64	5,592	4
2026-03-27	Chevallard, Daniel R.	Officer	Chief Financial Officer	Direct	Purchase	7,500	8.57	$64,275.00	12,886	4
2026-03-27	Schimmelpennink, Evert B.	Director,Officer	President, CEO and Secretary	Direct	Purchase	28,089	8.95	$251,396.55	77,289	4
2025-11-17	Olsson, Shawn	Officer	Chief Commercial Officer	Direct	Sale	10,000	26.06	$260,600.00	4,733	4
2025-11-07	Chevallard, Daniel R.	Officer	Chief Financial Officer	Direct	Purchase	2,198	22.74	$49,982.52	5,386	4
2025-11-07	Mccollum, James W	Director	-	Direct	Purchase	10,500	22.79	$239,295.00	10,500	4
2025-09-30	Versant, Vantage Ii Gp-Gp…	TenPercentOwner	-	Direct	Sale	132,944	46.26	$6,149,989.44	1,050,599	4
2025-09-18	Versant, Venture Capital …	TenPercentOwner	-	Direct	Sale	90,654	42.63	$3,864,580.02	1,183,543	4
2025-08-26	Versant, Ventures Vii Gp,…	TenPercentOwner	-	Direct	Sale	47,443	39.24	$1,861,663.32	1,274,197	4
2025-08-18	Versant, Venture Capital …	TenPercentOwner	-	Direct	Sale	30,628	38.56	$1,181,015.68	1,400,220	4
2025-07-10	Versant, Ventures Vii Gp-…	TenPercentOwner	-	Direct	Sale	191,376	34.00	$6,506,784.00	1,575,899	4
2025-06-27	Versant, Vantage Ii Gp-Gp…	TenPercentOwner	-	Direct	Sale	200,000	30.47	$6,094,000.00	1,767,275	4
2025-06-20	Versant, Ventures Vi Gp, …	TenPercentOwner	-	Direct	Sale	133,924	30.25	$4,051,201.00	1,967,275	4
2025-06-10	Versant, Vantage Ii Gp-Gp…	TenPercentOwner	-	Indirect	Sale	350,000	29.00	$10,150,000.00	1,248,789	4
2024-05-14	Chevallard, Daniel R.	Officer	Chief Financial Officer	Direct	Purchase	3,188	15.68	$49,987.84	3,188	4
2024-05-13	Mccollum, James W	Director	-	Indirect	Purchase	31,332	15.99	$500,998.68	525,565	4
2024-03-21	Ra, Capital Nexus Fund Ii…	Director,TenPercentOwner	-	Indirect	Purchase	998,009	15.03	$15,000,075.27	3,319,339	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

102.29%

Inst. Shares: 32,069,635

Shares Outstanding: 31,352,702

2025-12-31

115.32%

Inst. Shares: 33,227,230

Shares Outstanding: 28,813,164

2025-09-30

100.54%

Inst. Shares: 28,695,398

Shares Outstanding: 28,540,519

2025-06-30

87.15%

Inst. Shares: 24,470,124

Shares Outstanding: 28,079,071

2025-03-31

74.90%

Inst. Shares: 20,615,921

Shares Outstanding: 27,526,099

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	32,069,635	31,352,702	102.29%
2025-12-31	33,227,230	28,813,164	115.32%
2025-09-30	28,695,398	28,540,519	100.54%
2025-06-30	24,470,124	28,079,071	87.15%
2025-03-31	20,615,921	27,526,099	74.90%
2024-12-31	18,950,127	21,281,038	89.05%
2024-09-30	18,252,500	27,172,330	67.17%
2024-06-30	18,905,508	25,608,594	73.82%
2024-03-31	16,173,229	4,717,613	-
2023-12-31	30,309,741	1,959,091	-
2023-09-30	30,210,390	1,961,822	-
2023-06-30	31,184,556	1,956,244	-
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

LENZ Therapeutics, Inc. (LENZ) — SEC Financial Statements & Analysis

LENZ Therapeutics, Inc. (LENZ) is a biological products, (no diagnostic substances) company, incorporated in DE. LENZ Therapeutics, Inc. trades on Nasdaq as: LENZ. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), LENZ Therapeutics, Inc. reported a 297.74% year-over-year revenue growth, a Debt-to-Equity ratio of 0.08x, a Price-to-Sales (P/S) ratio of 8.96x (TTM), a Price-to-Book (P/B) ratio of 0.81x (TTM), at a market cap of $178.21M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 297.74%
Debt To Equity: 0.08x
P/S TTM: 8.96x
P/B TTM: 0.81x
Market Cap: $178.21M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is LENZ Therapeutics, Inc. in?

LENZ Therapeutics, Inc. (LENZ) operates in the Biological Products, (No Diagnostic Substances) industry.

What is LENZ's market cap?

LENZ Therapeutics, Inc. (LENZ) has a market capitalization of $178.21M as of 2026-06-30.

What exchange does LENZ trade on?

LENZ Therapeutics, Inc. (LENZ) trades on the Nasdaq.

Where is LENZ Therapeutics, Inc. incorporated?

LENZ Therapeutics, Inc. is incorporated in DE.